Altimmune Obesity Drug Sheds Fat With Less Muscle Loss in Trial
- Shares fall as company discontinues hepatitis drug program
- Weight-loss results similar to effects of diet and exercise
This article is for subscribers only.
Altimmune Inc.’s experimental weight-loss drug minimized muscle decline in a mid-stage trial, a sign that it can address a problem obesity drugmakers have been racing to solve. The shares fell as the company ended a separate drug development program in hepatitis.
More than 74% of patients’ weight loss came from fat tissue in the obesity drug trial, with only 25.5% coming from lean mass, Altimmune said in a statement, results similar to those often seen with diet and exercise programs.